EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access

Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study

Jungnam Joo iD, Joseph J Shearer iD, Anna Wolska iD, Alan T Remaley iD, James D Otvos iD, Margery A Connelly iD, Maureen Sampson iD, Suzette J Bielinski iD, Nicholas B Larson iD, Hoyoung Park iD, Katherine M Conners, Sarah Turecamo und 1 weitere

Circulation: Genomic and Precision Medicine · 2024

DOI: 10.1161/circgen.123.004312 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Circulation: Genomic and Precision Medicine, 2024. Verfasst von Jungnam Joo und 12 weiteren Autor:innen. Beteiligte Einrichtung: Office of Biostatistics Research (J.J.), National Heart, Lung, and Blood Institute, Bethesda, MD. Hauptthemen laut MEDLINE: Heart Failure. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Heart failure is heterogeneous syndrome with persistently high mortality. Nuclear magnetic resonance spectroscopy enables high-throughput metabolomics, suitable for precision phenotyping. We aimed to use targeted metabolomics to derive a metabolic risk score (MRS) that improved mortality risk stratification in heart failure. METHODS: Nuclear magnetic resonance was used to measure 21 metabolites (lipoprotein subspecies, branched-chain amino acids, alanine, GlycA (glycoprotein acetylation), ketone bodies, glucose, and citrate) in plasma collected from a heart failure community cohort. The MRS was derived using least absolute shrinkage and selection operator penalized Cox regression and temporal validation. The association between the MRS and mortality and whether risk stratification was improved over the Meta-Analysis Global Group in Chronic Heart Failure clinical risk score and NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels were assessed. RESULTS: The study included 1382 patients (median age, 78 years, 52% men, 43% reduced ejection fraction) with a 5-year survival rate of 48% (95% CI, 46%–51%). The MRS included 9 metabolites measured. In the validation data set, a 1 standard deviation increase in the MRS was associated with a large increased rate of death (hazard ratio, 2.2 [95% CI, 1.9–2.5]) that remained after adjustment for Meta-Analysis Global Group in Chronic Heart Failure score and NT-proBNP (hazard ratio, 1.6 [95% CI, 1.3–1.9]). These associations did not differ by ejection fraction. The integrated discrimination and net reclassification indices, and Uno’s C statistic, indicated that the addition of the MRS improved discrimination over Meta-Analysis Global Group in Chronic Heart Failure and NT-proBNP. CONCLUSIONS: This MRS developed in a heart failure community cohort was associated with a large excess risk of death and improved risk stratification beyond an established risk score and clinical markers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureMaleHumansAgedFemalePrognosisRisk FactorsBiomarkersCause of DeathChronic Disease

Stichwörter der Autor:innen

atrial fibrillationbiomarkerscardiovascular diseasesheart failurenatriuretic peptide, brain

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Office of Biostatistics Research (J.J.), National Heart, Lung, and Blood Institute, Bethesda, MD.
  • Heart Disease Phenomics Laboratory, Epidemiology and Community Health Branch (J.J.S., K.M.C., S.T., V.L.R.), National Heart, Lung, and Blood Institute, Bethesda, MD.
  • Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch (A.W., A.T.R., J.D.O.), National Heart, Lung, and Blood Institute, Bethesda, MD.
  • Labcorp, Morrisville, NC (M.A.C.).
  • Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD (M.S.).
  • Division of Epidemiology, Department of Quantitative Health Sciences (S.J.B.).

ORCID-Profile: Jungnam Joo, Joseph J Shearer, Anna Wolska, Alan T Remaley, James D Otvos, Margery A Connelly, Maureen Sampson, Suzette J Bielinski, Nicholas B Larson, Hoyoung Park, Véronique L Roger

Förderung

  • NIA NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Joo, J., Shearer, J. J., Wolska, A., Remaley, A. T., Otvos, J. D., Connelly, M. A., Sampson, M., Bielinski, S. J., Larson, N. B., Park, H., Conners, K. M., Turecamo, S., & Roger, V. L. (2024). Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study. Circulation: Genomic and Precision Medicine. https://doi.org/10.1161/circgen.123.004312

Vancouver

Joo J, Shearer JJ, Wolska A, Remaley AT, Otvos JD, Connelly MA, et al. Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study. Circulation: Genomic and Precision Medicine. 2024. doi:10.1161/circgen.123.004312

BibTeX
@article{Joo2024,
  author = {Joo, Jungnam and Shearer, Joseph J and Wolska, Anna and Remaley, Alan T and Otvos, James D and Connelly, Margery A and Sampson, Maureen and Bielinski, Suzette J and Larson, Nicholas B and Park, Hoyoung and Conners, Katherine M and Turecamo, Sarah and Roger, Véronique L},
  title = {Incremental Value of a Metabolic Risk Score for Heart Failure Mortality: A Population-Based Study},
  journal = {Circulation: Genomic and Precision Medicine},
  year = {2024},
  doi = {10.1161/circgen.123.004312}
}
Kostenlos starten →